Remyelination varies between and within lesions in multiple sclerosis following bexarotene.
James William L BrownFerran Prados CarrascoDaniel R AltmannBaris KanberJonathan StuttersNicholas G CunniffeJoanne Louise JonesZoya G GeorgievaEdward J NeedhamCyrus DaruwallaClaudia Gandini Wheeler-KingshottPeter ConnickSiddharthan ChandranRobin FranklinDavid MacManusRebecca SamsonAlasdair J ColesDeclan T ChardPublished in: Annals of clinical and translational neurology (2022)
Remyelination varies markedly within and between lesions. The greater remyelinating effect in GM lesions is congruent with neuropathological observations. For future remyelination trials, whole GM lesion measures require less complex post-processing compared to WM lesions (which require voxel level analyses) and markedly reduce sample sizes.
Keyphrases